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Introduction: Glaucoma is a chronical progressive optical neuropathy with characteristic morphological 
changes on the desk of the optical nerve and retinal neurofibrillary layer as well as progressive death of 
ganglion cells with loss of sight in the absence of other eye diseases and congenital anomalies. It is called 
(EGC 2014) in the newest definition from the European association for Glaucoma. The basic medication 
for treatment of this illness are the prostaglandin derivatives from which the travoprost is the latest in a 
series of derivatives. 
Goal:  Discovering the unwanted side effects of Travoprost 
Discussion: The latest estimates of WHO (World health organization) are the on a global level cancer 
takes the first position, the cardiovascular illnesses second and blindness takes the third position as global 
challenges that should be addressed. The Glaucoma impacts 9-12% of the people that have blindness in 
the world, i.e. 2,5 million people every year. WHO predicts that the percentage with rise to 30% by the 
year 2020. From this the need for daily findings of new medication for suppressing this illness occurs. 
Conclusion: In the conclusion we can say that the right and on time diagnosis of the glaucoma and the 
effective treatment is the only mechanism in the fight with this illness.  
Although there are side effects, the travoprost today is one of the basic agents in the fight with Glaucoma. 
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Introduction 
After the discovery of travoprost as a prostaglandin agent and its powerful effect in 
reducing intra ocular pressure, it has become part of modern protocols for the treatment of 
glaucoma. [1] The travaprost is used individually as a mono therapy, but it also can be used in a 
combination especially with timolol maleate from the group of beta blockers. With the 
abovementioned combination, increases the effect for lowering the intraocular pressure up to 
30% [2]. Besides the good features like every medication it has its unwanted side effects to 
which this paper is dedication on. 
The unwanted side effects can be divided into several groups: 
Very common (they occur to more than 1 out of 10 users) which include changing the color of 
the eyes with deposition of brown pigment in the iris. 
Common (they occur to less than 1 out of 10 users) which include a burning, itching feeling, 
feeling of a foreign object in the eye and pain. 
Less common (they occur to less than 1 out of 100 users) which include headache, redness in the 
eyes, conjunctivitis, blurred vision, blepharitis, pruritus 
Other side effects- symptoms of an allergic reaction, psychiatric disorders, disorders of the 
nervous system, hearing impairment, cardiovascular disorders, respiratory disorders, disorders in 
the digestive tract, musculoskeletal, skin and other disorders [3,4.5,6 and 7]. For us the most 
important are the effects on the eyes like the change of the eyelashes and eyebrows in the sense 
of increased length, thickness, direction of growth and number of eyelashes. Swelling of the 
eyelids, macular edema, keratitis, diplopia, ptosis, cysts on the iris and retina ablation. [8.9.10]   
 
Materials and methods. 
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For the needs of this study 96 patients where monitored of which 61 patient used the 
travoprost on two eyes and 35 patients in just one eye. 
All of the patients use the travoprost as a mono therapy. From the monitored 96 patients 54 are 
men and 43 women. 
 
Table 1 
 Number of parients In both eyes In one eye 
Men 54 33 21 
Women 42 28 14 
Total 96 61 35 
 
 
The patients have been monitored for a period of one year and in that time period 4 
examinations were made in every trimester separately. Notice, some of the patients were 
examined more often because of the condition of the illness, but those parameters are not taken 
in regard for this study. One symptom is monitored from every group, 
Deposition of pigment in the iris. Pain in the eye, redness in the eyes and enlargement of 
the eyelashes. All of the patients have glaucoma in an open angle and there are no other eye 
illnesses and diplopia under 2D in plus and minus. For every patient visual acuity measurement 
is taken, measuring the tone, gonioscopy, perimetry is regularly performed. 
 
Table 2 
 Patience with 
therapy in two 
eyes 
Patience with 
therapy in one 
eye 
Total 
Deposition of 
pigment 
7(11.47%) 4(11.42%) 11(11.46%) 
Pain 5(8,12%) 2(5.72%) 7(7.22%) 
Eye redness 5(8.12%) 2(5.71%) 7(7.22%) 
Enlarged 
eyelashes 
10(16.4%) 6(17,14%) 16(16,66%) 
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Results: 
The received results were in the framework of our expectations. With the deposition of pigment, 
we can see that our total result is 11.11% which is a relatively small percentage. We received 
similar numbers during the examination regarding the pain which is 7%. I would like to use this 
opportunity to mention that none of the patients refused to use the therapy or tried to change it 
because of the pain. 
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We received an identical result with the redness in the eyes as the pain and from this we 
can conclude that the pain and the redness in the eyes are directly proportional. The biggest 
percent of unwanted side effects are with the enlargement of the eyelashes. Up to 16.66% to such 
side effect there were no reactions from the patients, even some patients that were female were 
grateful. 
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Summary 
In the summary we can freely say that the Travoprost is an agent accessible for the patients 
with a relatively small percentage of unwanted side effects that are easily manageable and are 
not the reason to stop the therapy, with a good positive effect for lowering the intra ocular 
pressure. Some female patients are even satisfied with the side effect on the eyelashes. The study 
confirms that the unwanted side effect differs very little between the patients that use this agent 
in one or both eyes. 
 
Conclusion: 
In the conclusion we can say that the right and on time diagnosis of the glaucoma and the 
efficient treatment is the only mechanism in the fight against this illness. Although there are side 
effects, the travoprost today is one of the basic agents in the fight with Glaucoma. 
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